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 Amyotrophic Lateral Sclerosis (ALS) is a fatal neurodegenerative disease that 
deteriorates upper motor neuron and lower motor neurons of the central nervous system. 
Jean-Marie Charcot, a French neurologist and physiologist, discovered the disease in his 
laboratory between 1869-1874. Charcot named and diagnosed the first case of 
amyotrophic lateral sclerosis after the pathophysiology that he witnessed in his 
laboratory. He broke down the disease into root words from the Latin language 
describing his findings, “a” meaning no or none, “myo” meaning muscle, and “trophic” 
meaning nourishment (Kumar 2011).  Amyotrophic therefore refers to no muscle 
nourishment, when a muscle does not receive the proper nourishment and lacks physical 
use; the muscle atrophies or wastes away (See Appendix A). The lateral portion of the 
disease refers to the area of the spinal cord that the descending efferent motor tracts run, 
and sclerosis means scarring. "Lateral sclerosis" refers to hardening of the anterior and 
lateral corticospinal tracts as neurons in this tract degenerate and are replaced by gliosis. 
Charcot compiled his findings and documented ALS as a separate motor neuron disease 
in 1879 (Kumar 2011). Charcot’s influence on the field of medicine opened the way for 
the study of neurological disorders through correlation of clinical observations and 
pathological discoveries. He was an insightful figure who lead the way in distinguishing 
neurological diseases and finding better treatment options for those suffering from these 
disorders. 
 The epidemiology of ALS is not entirely understood, as systematic epidemiology 
has not been thoroughly recorded. Though this information is incomplete, it is understood 
that ALS occurs throughout the world because of the disease’s distinct pathology. The 
disease does not seem to have any cultural boundaries and is predominately a sporadic 
disease. ALS is shown to be roughly 90% sporadic and 10% familial worldwide. The 
majority of individuals with ALS are between the ages of 50-60 years old but familial 
cases have been shown to affect individuals as young as teenagers also (Bäumer 2014). 
Being diagnosed with ALS under the age of thirty happens in only 5% of cases in the 
United States. The literature shows that roughly 30,000 Americans are currently 
diagnosed with ALS and that males are slightly more affected than women, with a 
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 diagnosis ratio of 1.5 to 1, possibly due to protective hormonal factors in women. 
Western countries prevalence on average is 5.2 per every 100,000 people (Wijesekera 
2009). It is well understood that ALS is not contagious and has no socioeconomic or 
racial boundaries: presently, the only known risk is having immediate family members 
who have been diagnosed with ALS.  
 The major pathogenesis of ALS is the degeneration of Betz cells and other 
pyramidal cells that are located in the primary motor cortex of the frontal lobe. The 
degeneration of the corticospinal tracts that begin in the precentral gyrus, pass through 
the internal capsule, cerebral peduncles, brain stem, and eventually spinal cord whither 
away. Degeneration of anterior horn cell lower motor neurons, and reactive gliosis are 
also present as the disease progresses (See Appendix B). Astrocytes, a type of glial cell 
found in the spinal cord, are vital to the healthy functioning of the central nervous 
system. Some propose that when these cells fail to reabsorb glutamate, it causes the 
neurotransmitter to reach toxic levels and leads to scarring in the lateral regions of the 
spinal cord, also disrupting neural signaling (Leigh 1995). The degeneration of motor 
neurons and subsequently the lateral cotricospinal tracts results in motor weakness with 
no clear indication of sensory disruption. The Corticospinal Tract has three divisions, the 
crossed lateral corticospinal tract, the partially uncrossed anterior corticospinal tract, and 
the fully uncrossed corticospinal tract. Ninety percent of the Corticospinal Tract is fully 
crossed fibers that travels within the contralateral lateral funiculus and decussate at the 
pyramidal decussation in the lower medulla. Eight percent of the Corticospinal Tract, or 
the partially uncrossed Corticospinal Tract travel within the ipsilateral ventral funiculus 
while the remaining two percent are the fully uncrossed lateral Corticospinal Tract that 
safeguard against incomplete damage (Sahley 2014). All three divisions are efferent 
descending fiber pathways that synapse with lower motor neurons in the ventral horn of 
the spinal cord. The modalities of these tracts are willed and skilled voluntary motor 
control, especially activation of skeletal muscle of the patient’s extremities. While the 
lateral division innervates distal muscle, the anterior division innervates axial muscle. 
Damage to these motor tracts can be seen in patients with ALS, especially using fluid-
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 attenuated inversion recovery magnetic resonance imaging (FLAIR MRI) as seen in 
Appendix C and Appendix D showing degeneration of these areas. This type of test in 
which hyperintensity in the posterior limb of the internal capsule is consistent with 
cotricospinal tract degeneration is seen through transverse and horizontal cut images of 
the brain (da Rocha 2004).  The precentral gyrus of the frontal lobe is the primary motor 
cortex of the brain, also known as Brodmann area four which contains Betz cells. These 
cells contain long axons that synapse with motor neurons that directly connect to skeletal 
muscles (Manshadi 2014). When this region experiences pathology, such as in ALS, 
hyperinstesity of the area is shown and neurologists can determine if the corticospinal 
tracts are intact and healthy or degeneration is occurring. 
 Since ALS degenerates both upper and lower motor neurons and their respective 
tracts as noted above, the disease is considered unique to each individual. Lesions to 
upper motor neurons of this tract will cause spastic paralysis, disuse atrophy, and hyper-
reflexia. Lesions to the lower motor neurons will cause flaccid paralysis, significant 
atrophy, and hypo-reflexia (Manshadi 2014). Before diagnosis of the disease, many 
patients have difficulty walking due to foot drop, notice weakness in a limb, or 
experience fasciculations (twitching) of the muscles. As the disease progresses, many 
patients experience muscle spasticity, muscle atrophy, dyspnea, and dysphagia 
(Zoccolella 2006). Complications with patients can also arise when the pathology of ALS 
affects the corticobulbar tracts, which activate muscles served by cranial nerves. Muscles 
of mastication – particularly the masseter that elevates the mandible, the temporalis that 
elevates and draws back the mandible, and the medial and lateral ptergoids that protrude 
and elevate the mandible – can degenerate due to ALS. The mixed mandibular branch of 
the trigeminal cranial nerve V that originates in the trigeminal motor nucleus innervates 
these muscles, and if these muscles experience atrophy, patients will lose voluntary 
movement of them. The tensor tympani and tensor veli palatini in the nasopharynx will 
tense the velum, which is active during swallowing (Sahley 2014). If the patient does 
experience muscle atrophy or paralysis in the muscles of mastication, a feeding tube, 
usually a percutaneous endoscopic gastrostomy tube is used to aid in nutritional eating 
3
Naumann: Amyotrophic Lateral Sclerosis
Published by EngagedScholarship@CSU, 2015
 and drinking that cannot otherwise be possible under the patient’s voluntary control 
(Czell 2013). Cranial nerves V, VII, IX, X, and XI all contain special somatic-motor 
components. Trouble speaking arises from innervation of the accessory nerve XI to the 
sternocleidomastoid muscle that function in opening the mouth used for speaking as well 
as eating. Cranial nerve VII, the Facial nerve, innervates muscles of facial expression, 
and cranial nerves IX and X, the Glossopharyngeal and Vagus nerve, innervate muscles 
of the pharynx and larynx, which play a roll in swallowing and speech (Sahley 2014). 
Pathology to these respective muscles will cause a patient to take a multidisciplinary 
course of therapy, medication, and devices to help prolong life and maintain movement 
of the affected areas.  
 Diagnosing ALS is a separate complication that physicians experience while 
trying to aid patients with this disease. Generalized muscle weakness without sensory 
complications can be seen in a number of disorders such as polymysitis, dermatomyositis, 
thyroid disorders, electrolyte abnormalities, and autoimmune motor neuropathies 
(Gordon 2011). ALS is therefore diagnosed by ruling out other disorders. Upper motor 
neuron damage will result in the Babinski reflex, in which a patient’s sole of the foot is 
stimulated and the toes curl inward and down. This reflex, which should only happen in 
young children, is a sign of upper motor neuron damage that can be caused by ALS. 
Physicians will also look for stiffness and spasticity of the muscles of the patient while 
also checking brisk reflexes using a reflex mallet to rule in upper motor neuron damage. 
Difficulty of producing sounds and articulating words, respectively dysphonia and 
dysarthria are also common among patients with bulbar onset ALS patients (Zoccolella 
2006). Physicians can rule complications with those cranial nerves when a patient 
exhibits a loss of gag reflex or masseter reflex of the trigeminal nerve V, which will be 
quite noticeable. Approximately two thirds of patients with ALS initially present with 
muscle weakness in the upper or lower limbs and approximately one fourth of patients 
presents with progressive dysarthria and dysphagia, also known as bulbar-onset ALS.  
 Since ALS is a rapidly progressive neurological disease, there is no current cure. 
As the scientific community is in search of a cure for neurodegenerative diseases, it 
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 currently takes a multidisciplinary course of action to prolong life in patients diagnosed 
with ALS. Glutamate, the mostly excitatory neurotransmitter in the central nervous 
system, may play a role in ALS. Excess glutamate can be toxic and cause degeneration in 
the central nervous system. Excitotoxicity can occur when glutamate receptors, such as 
NMDA or AMPA, are over activated. Once these receptors are open, excess 
accumulation of intracellular calcium and sodium occurs leading to neuronal death or 
injury (see Appendix E). The only FDA approved drug to counter this problem and to aid 
the slowing of ALS is Riluzole, or brand name Rilutek. It is a glutamate-release inhibitor 
that is shown to prolong patient’s survival by up to four months, and lengthen the time 
needed before ventilation support must be given for survival (Gordon 2011).  
Physical and occupational therapists are another source of healthcare provision 
that can help manage a patient’s ALS. Pain is not a direct consequence of ALS but 
immobility of the body and joint contractures can cause weakness, muscle cramps, and 
pain. As a result, physical therapists can help through range-of-motion exercises and 
accessing limb strength. As the disease progresses, muscles will start to weaken and 
stiffen, physical therapists may also help to loosen the muscles and prevent contractures 
from occurring. Low impact aerobic exercises may aid patients with fatigue, depression, 
and improve cardiovascular health. Occupational therapist can develop and address 
skilled motor functions that help aid patients in daily activities. Occupational therapist 
can also suggest at home changes such as ramps or walkers that help individuals remain 
mobile with the least amount of stress on the body. Speech pathologist and respiratory 
therapists will also be needed to aid in the progression of ALS, especially patients that 
have bulbar-onset ALS. Eventually all muscles that aid in breathing, specifically when 
the diaphragm and chest wall fail to function properly, ventilation support must be given 
for survival (Naganska 2011). Since ALS is a fatal disease, the goal of therapy is to aid 
and achieve the highest quality of life for patients with ALS. Other non-pharmacological 
therapies can help manage the numerous symptoms that may arise in ALS patients 
through communication devices, voice amplifiers, and wheelchairs, as seen with one of 
the most famous ALS patients in the world, Stephen Hawking.  
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  Since ALS is rapidly progressive in nature, life expectancy is three to five years 
after being diagnosed, though roughly 10% of ALS patients survive for ten or more years 
(Gordon 2011). Overall, ALS is considered a troublingly harsh and multifaceted form of 
neurodegenerative disease. While motor function is progressively being lost, patients can 
also undergo dementia and cognitive complications. Understanding the anatomy, clinical 
symptoms, and diagnosis of the disease can help healthcare providers prolong life and try 
to achieve the greatest quality of life for individuals who are diagnosed with amyotrophic 
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Clinical features of muscle 
 
(A): Proximal and symmetrical upper limb wasting which will not allow the patient to lift 
his arms against gravity  
 
(B): wasting of supraspinatus, infraspinatus, and
superior and inferior to the scapula
 
(C): Wasting of the thumb 
 
(D): Wasting of the tongue muscles can make it difficult for patients to
when speaking  
 
[Muscle atrophy in ALS patient. Digital image.
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 Histologic features of a patient with ALS, this image is of the spinal anterior horn where 
degeneration, loss of neurons, and severe gliosis is occurring. The circled part of the 
image is of a healthy Clarke’s column, the relay center for unconscious propr
 
Amyotrophic lateral sclerosis, spinal cord shows gray and thin or atrophic anterior nerve 
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 Appendix C 
(A) Shows the result of the control group.  
(B) Shows the results for the ALS patients. 
(C) Shows the statistical comparison is shown between the patients. 
 
 
[Kollewe, K., Körner, S., Dengler, R., Petri, S., & Mohammadi, B. (2012). Magnetic Resonance 
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 (A) Image of a control subject showing subcortical precentral gyral isointensity.
 
(B) Image of control subject showing subcortical precentral gyral hypointensity.
 
(C) Image of ALS patient showing pathologic hyperintensity in the cortical and 




[da Rocha, A., Oliveira, A., Fonseca, R., Maia, A., Buainain, R., & Lederman, H. (2004). 
corticospinal tract compromise in amyotrophic lateral sclerosis with brain MR imaging: relevance of 




























The mechanisms that operate in the neurodegeneration of ALS is not entirely understood 
but must be multifactorial. Most of the literature note that there is a, “complex interaction 
of glutamate excitoxicity, generation of free radicals, cytoplasmic protein aggregates, 
SOD1 enzymes, combined with mitochondrial dysfunction, and disruption of axonal 
transport processes through accumulation of neurofilament intracellular aggregates. 
Mutations in TARDBP and FUS result in formation of intracellular aggregates, which are 
harmful to neurons. Activation of microglia results in secretion of proinflammatory 
cytokines, resulting in further toxicity. Ultimately, motor neuron degeneration occurs 
through activation of calcium-dependent enzymatic pathways” (Kiernan 2011). 
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